Family · Pharmaceutical analytical standards
Fluoxetine
An SSRI antidepressant discovered in the United States in the early 1970s, first marketed in Belgium in 1986 and approved in the United States in 1987: it is used for depression, obsessive-compulsive disorder, bulimia and panic disorder. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?The research started from a molecule similar to the antihistamine diphenhydramine: biochemist David T. Wong suggested testing its derivatives on serotonin reuptake, and fluoxetine proved the most selective.
No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
